 | | Gut microbiota determine insulin sensitivity |
|  | | Overview |
|
 | | Gutmicrobiota in health and disease |
|  | | Metabolic active acterial phylae |
|
 | | Gut microbiota |
|  | | Gut microbiota |
|
 | | Human microbiome projects |
|  | | Symbiont role |
|
 | | Germfree mice and metabolism |
|  | | Specific gut microbiota seem to affect body fat composition |
|
 | | Gutmicrobiota habit is a Transmissible trait |
|  | | Gut microbiota in human disease |
|
 | | Gutmicrobiota products in plasma associated with developing insulin resistance and CVD |
|  | | Human gutmicrobiota and enterotypes |
|
 | | Enterotypes and dietary composition |
|  | | Gutmicrobiota in gutphysiology |
|
 | | Microbiota products and insulin resistance |
|  | | Microbiota products and cardiovascular disease |
|
|
|
 | | Manipulating gutmicrobiota by fecal transplant: effect on insulin resistance |
|  | | Objectives FATLOSE trial |
|
 | | Donors |
|  | | FATLOSE trial (Faecal Administration To LOSE metabolic syndrome) |
|
|  | | Outcome measures |
|
 | | Baseline characteristics |
|  | | Effect donorfaeces on intake/metabolism: |
|
 | | Effect donor faeces on whole body insulin sensitivity |
|  | | Effect donor faeces on hepatic insulin sensitivity |
|
 | | Changes in fecal butyrate and proprionate |
|  | | Effect donorfaeces on gutmicrobiota |
|
 | | Fecal samples before and after lean donor Tx |
|  | | Small intestinal biopsy before and after lean donor Tx |
|
 | | Caution |
|  | | Manipulating gutmicrobiota by broad spectrum antibiotics : effect on insulin resistance |
|
 | | Antibiotic use and obesity |
|  | | Study protocol |
|
 | | Baseline characteristics AV trial- Median (range) |
|  | | Periferal insulin resistance |
|
 | | Hepatic insulin resistance |
|  | | Gut microbiota and human metabolism |
|
 | | Take home message |
|
CVC_nieuwdorp_def (PDF 2,4MB)
Deel deze pagina met collega's en vrienden: